Frequency follows Astellas pact with $62M round to bankroll PhII of lead regenerative drug
A few days ago Frequency Therapeutics got some high profile endorsement on its small molecule strategy for regenerative medicine, when Astellas offered $80 million upfront to partner on their lead drug. As it turns out, the Japanese pharma wasn’t the only one intrigued by the platform and upcoming Phase II study of FX-322.
Perceptive Advisors has jumped in to lead a $62 million Series C, which also drew Deerfield Management, RTW Investments and Mizuho Securities Principal Investment. Polaris, Taiwania, Axil and CoBro also doubled down on their existing bet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.